Expert Viewpoints in Leukemia Care: Recent Episodes
ReachMD
Amid the evolving therapeutic landscape for two of the most common types of leukemia in adults, chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), it’s now more important than ever to stay up to date. Expert Viewpoints in Leukemia Care is designed to help healthcare professionals do just that, with key thought leaders offering insights on management strategies for patients living with CLL and AML Sponsored by
Medical Affairs ABBV-US-00213-MCVersion 1.0, Approved September 2020
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nicole Lamanna, MD
The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understandings of the AML genomic landscape, it’s become possible to develop targeted AML therapies. Joining Dr. Charles Turck to explore Venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.